Turkish Journal of Nephrology
Case Report

Everolimus-Associated Thrombotic Microangiopathy and Acute Kidney Injury in a Patient with Breast Cancer

1.

İzmir Tepecik Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Nefroloji Bölümü, İzmir, Türkiye

2.

İzmir Tepecik Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, İzmir, Türkiye

Turkish J Nephrol 2016; -1: Supplement 86-88
DOI: 10.5262/tndt.2016.17
Read: 1747 Downloads: 675 Published: 01 February 2019

Thrombotic microangiopathy is a pathological condition caused by several factors including drugs, and characterized by endothelial injury and small vessel occlusion. It may cause severe acute kidney injury. Everolimus, a mammalian target of Rapamycin inhibitor, is a macrolide antibiotic widely used in clinical conditions because of its anticancer and immunosuppressive effects. Recently it has been approved for use in breast cancer at a dose of 10 mg/day in combination with exemestane, an aromatase inhibitor. In the literature a few cases of everolimus-induced thrombotic microangiopathy and acute kidney injury in breast cancer patients have been reported. Here we reported the management of a breast cancer patient with everolimus-induced thrombotic microangiopathy and severe acute kidney injury with emphasis on close monitoring of kidney functions. 

Files
EISSN 2667-4440